Mental Health, FDA Bills Advance in House; Senate releases FDA bill
The House Energy and Commerce Health Subcommittee today passed, as amended, the Restoring Hope for Mental Health and Wellness Act (HR 7666), bipartisan legislation that would reauthorize more than 30 programs set to expire in September that support mental health care, prevention, education and workforce training. The bill includes legislation backed by the AHA that would reauthorize and expand a program that treats maternal depression to include mental health and substance abuse disorders, and would require the Secretary of Health and Human Services to maintain a line of national hotline to provide mental health and addictions resources. pregnant and postpartum women and their families. Among other provisions, the bill would create a Behavioral Health Crises Coordinating Office within the Substance Abuse and Mental Health Services Administration and require the Secretary of Health and Human Services to publish best practices for a continuum of care in crisis.
The committee also voted unanimously to advance legislation (HR 7667) to reauthorize the Food and Drug Administration’s user fee programs, which provide funding for the agency to review drugs, devices and biological products. Among other provisions, the bill would include drugs on the FDA’s shortage list in a pilot program to designate advanced manufacturing technologies.
The Senate Committee on Health, Education, Labor and Pensions yesterday released a bill for discussion to reauthorize FDA user fee agreements, which would also establish a new regulatory framework for the review and approval of laboratory-developed tests.